influenza
virus
huge
impact
public
health
current
influenza
vaccin
need
updat
annual
protect
poorli
antigen
drift
variant
novel
emerg
subtyp
vaccin
influenza
improv
two
import
way
either
induc
broadli
protect
immun
respons
decreas
time
vaccin
product
relev
especi
pandem
outbreak
review
outlin
current
effort
develop
socal
univers
influenza
vaccin
describ
antigen
may
induc
broadli
protect
immun
novel
vaccin
product
platform
facilit
time
avail
vaccin
influenza
virus
belong
famili
orthomyxovirida
divid
three
type
b
c
influenza
virus
infect
mani
differ
speci
respons
substanti
morbid
mortal
season
epidem
furthermor
zoonot
spillov
event
influenza
could
potenti
caus
novel
pandem
influenza
virus
divid
subtyp
base
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
accord
ha
design
virus
classifi
two
group
consid
group
belong
group
influenza
b
unlik
influenza
virus
anim
reservoir
predominantli
infect
human
influenza
b
divid
two
phylogenet
lineag
yamagatalik
victorialik
virus
lower
mutat
rate
also
contribut
season
influenza
activ
consider
influenza
c
virus
rare
isol
diseas
caus
virus
usual
limit
mild
symptom
children
season
pandem
influenza
virus
huge
public
health
consequ
unit
state
alon
total
annual
econom
burden
season
influenza
estim
billion
introduct
novel
subtyp
influenza
viru
human
popul
may
lead
pandem
outbreak
happen
three
time
previou
centuri
spanish
flu
caus
virus
asian
flu
caus
virus
hong
kong
flu
caus
virus
recent
influenza
pandem
caus
influenza
viru
swine
origin
pandem
outbreak
influenza
associ
excess
morbid
mortal
sever
occas
zoonot
transmiss
avian
influenza
virus
bird
human
subtyp
occur
sometim
lead
fatal
diseas
although
thu
far
humantohuman
transmiss
remain
limit
subtyp
infect
virus
particular
constitut
pandem
threat
demonstr
recent
limit
number
mutat
ha
viral
polymeras
requir
make
airborn
transmiss
highli
pathogen
avian
influenza
virus
subtyp
possibl
inde
adapt
mutat
alreadi
found
circul
virus
influenza
virus
acquir
addit
genet
chang
rapidli
either
mutat
reassort
virus
adapt
replic
mammalian
host
current
exist
influenza
vaccin
produc
use
labor
intens
timeconsum
product
method
reli
avail
embryon
chicken
egg
face
outbreak
caus
novel
emerg
subtyp
method
suffer
logist
problem
preclud
adequ
respons
delay
avail
suffici
number
vaccin
dose
may
disastr
consequ
public
health
discuss
review
limit
current
vaccin
highlight
press
need
gamechang
vaccin
induc
longlast
immun
wide
rang
influenza
virus
current
use
vaccin
protect
season
pandem
influenza
viru
infect
predominantli
aim
induct
antibodi
direct
specif
site
highli
variabl
head
domain
ha
surfac
glycoprotein
lesser
extent
na
glycoprotein
sinc
error
rate
influenza
viru
high
due
low
fidel
rna
polymeras
complex
mutat
viral
genom
accumul
quickli
select
pressur
exert
viru
neutral
antibodi
induc
previou
infect
vaccin
vaccin
induc
ha
globular
headspecif
antibodi
becom
less
effect
mutat
ha
accumul
extent
vaccineinduc
haspecif
antibodi
longer
recogn
target
process
known
antigen
drift
current
use
vaccin
gener
trival
contain
compon
two
influenza
strain
one
influenza
b
strain
strain
use
season
vaccin
select
annual
approxim
eight
month
start
season
vaccin
campaign
select
vaccin
compon
base
predict
strain
like
circul
subsequ
influenza
season
although
method
mathemat
model
influenza
viru
evolut
develop
aid
predict
recommend
best
possibl
vaccin
strain
remain
difficult
vaccin
strain
match
epidem
strain
potenti
lead
higher
morbid
mortal
differ
formul
inactiv
vaccin
use
parenter
administr
whole
virion
split
virion
subunit
vaccin
split
virion
subunit
vaccin
initi
develop
overcom
advers
reaction
associ
whole
virion
vaccin
shown
compar
immunogen
less
reactogen
whole
virion
prepar
sinc
inactiv
trival
split
virion
vaccin
commonli
use
season
vaccin
paradox
efficaci
vaccin
age
group
risk
young
elderli
actual
lower
healthi
adult
altern
inactiv
formul
live
attenu
influenza
vaccin
laiv
produc
reassort
gene
segment
encod
desir
ha
na
glycoprotein
cold
adapt
attenu
strain
vaccin
administ
intranas
induc
mucos
immun
addit
system
antibodi
cell
respons
close
mimick
immun
respons
induc
natur
influenza
viru
infect
low
immunogen
inactiv
vaccin
children
laiv
may
better
suit
protect
age
group
inde
shown
intranas
administr
laiv
children
year
age
signific
increas
bcell
tcell
respons
could
induc
sustain
least
one
year
vaccin
howev
whether
univers
vaccin
immunolog
naiv
children
fact
advis
strategi
remain
topic
debat
vaccin
children
risk
develop
sever
complic
due
influenza
cours
highli
recommend
vaccin
otherwis
healthi
children
risk
develop
sever
complic
inactiv
vaccin
may
interfer
develop
heterosubtyp
immun
otherwis
induc
follow
natur
infect
even
though
situat
childhood
vaccin
laiv
may
advantag
trival
inactiv
vaccin
tiv
suffer
similar
problem
regard
product
like
inactiv
vaccin
product
process
laiv
still
predominantli
eggbas
difficult
scaleup
vaccineinduc
antibodi
also
direct
mostli
head
domain
ha
thu
risk
lose
effect
face
antigen
drift
shift
addit
laiv
product
challeng
like
incompat
certain
ha
na
combin
backbon
viru
creat
replic
compet
vaccin
viru
clearli
current
avail
influenza
viru
vaccin
strategi
leav
lot
desir
induct
strainspecif
antibodi
direct
head
domain
ha
may
efficaci
vaccin
strain
match
anticip
epidem
strain
case
antigen
drift
case
pandem
outbreak
caus
newli
emerg
influenza
virus
avail
vaccin
induc
broadli
protect
immun
desir
overcom
import
public
health
issu
vaccin
induc
antibodi
conserv
protein
region
thereof
activ
arm
immun
system
like
cellmedi
immun
respons
conserv
protein
word
vaccin
hit
nail
head
compar
current
regimen
novel
approach
vaccin
influenza
improv
two
import
way
either
induc
broadli
protect
immun
respons
decreas
time
product
outlin
current
effort
field
develop
socal
univers
influenza
vaccin
review
figur
distinguish
two
approach
approach
base
identifi
target
induc
broadli
protect
immun
base
integr
target
novel
vaccin
platform
although
categori
artifici
cours
substanti
overlap
two
togeth
roughli
encompass
state
art
univers
vaccin
develop
antibodi
na
limit
product
progeni
viru
antibodi
ha
na
follow
adcc
signal
nk
cell
phagocytosi
shown
virusspecif
lymphocyt
virusspecif
lymphocyt
possess
cytolyt
activ
influenza
genom
encod
protein
eight
segment
rna
ha
na
np
pa
protein
variabl
conserv
among
avian
human
viru
isol
shown
larg
studi
analyz
sequenc
viru
isol
collect
past
year
na
protein
found
contain
sequenc
complet
conserv
least
virus
howev
comparison
sequenc
pa
np
protein
show
sequenc
amino
acid
complet
conserv
least
even
much
avian
human
influenza
viru
isol
although
ha
gener
consid
highli
variabl
one
amino
acid
sequenc
conserv
type
virus
inform
may
use
attempt
identifi
conserv
target
requir
make
univers
vaccin
howev
simpli
broaden
respons
alreadi
prove
challeng
discuss
antibodi
directli
neutral
influenza
virus
bind
antigen
site
viral
ha
therefor
interf
bind
cellular
receptor
previous
mention
neutral
antibodi
induc
follow
natur
infect
vaccin
target
highli
variabl
globular
head
ha
molecul
howev
rule
thumb
antibodi
crossprotect
differ
ha
subtyp
distantli
relat
strain
subtyp
addit
directli
neutral
viru
particl
antibodi
also
mediat
number
nonneutr
immunolog
function
figur
includ
block
fusion
viral
endosom
membran
innat
immun
system
activ
complementmedi
lysi
phagocytosi
antibodi
depend
cellmedi
cytotox
adcc
adcc
occur
effector
cell
case
influenza
mostli
natur
killer
nk
cell
recogn
fc
portion
igg
bound
viral
antigen
present
cell
surfac
interact
nk
cell
fc
portion
igg
activ
pathway
result
dna
damag
apoptosi
well
releas
granzym
b
perforin
antivir
cytokin
eventu
lead
death
influenza
viru
infect
cell
nonneutr
antibodi
often
direct
conserv
region
receiv
consider
attent
quest
univers
vaccin
develop
viral
antigen
consid
induc
humor
immun
respons
either
neutral
nonneutr
discuss
ha
surfac
glycoprotein
respons
viral
bind
fusion
host
cell
membran
sinc
ha
abundantli
present
viral
particl
attract
host
immun
system
target
molecul
antibodi
date
differ
subtyp
shown
exist
detect
bat
precursor
molecul
cleav
specif
proteolyt
cleavag
site
ha
head
form
central
portion
ha
stem
form
nand
ctermin
part
full
ectodomain
cleavag
site
attract
interest
vaccin
target
essenti
viral
replic
therefor
highli
conserv
among
influenza
b
virus
influenza
b
virus
consist
two
antigen
distinct
lineag
shown
conjug
peptid
vaccin
target
ha
cleavag
site
induc
antibodi
respons
abl
protect
mice
challeng
influenza
b
lineag
serv
univers
influenza
b
vaccin
similar
strategi
attempt
influenza
achiev
decreas
mortal
morbid
fulli
protect
vaccin
mice
decreas
mortal
induct
heterosubtyp
immun
could
also
demonstr
mice
immun
fusion
peptid
target
epitop
globular
head
instead
stem
advantag
sinc
readili
access
antibodi
though
rare
conserv
region
ha
globular
head
exist
recent
conserv
epitop
identifi
influenza
viru
use
broadli
neutral
human
antibodi
name
antibodi
shown
interact
conserv
region
otherwis
hypervari
receptor
bind
site
ha
globular
head
exampl
recogn
small
conserv
element
receptorbind
site
found
neutral
strain
multipl
influenza
subtyp
includ
anoth
human
monoclon
antibodi
design
found
insert
receptorbind
pocket
effect
mimick
sialic
acid
receptor
shown
neutral
strain
test
howev
heterosubtyp
immun
demonstr
furthermor
potenti
crossreact
antibodi
shown
neutral
multipl
ha
strain
subtyp
includ
studi
obvious
requir
howev
antibodi
could
provid
clue
new
target
univers
vaccin
develop
although
induc
antibodi
ha
cleavag
site
globular
head
may
interest
univers
vaccin
develop
far
attent
focus
induc
antibodi
stem
region
stem
antibodi
group
influenza
typic
induc
infect
vaccin
remain
subdomin
headspecif
antibodi
due
limit
access
stem
interestingli
infect
human
pandem
led
induct
broadli
neutral
antibodi
respons
epitop
ha
head
stem
region
suggest
induct
broadli
reactiv
antibodi
univers
vaccin
possibl
group
ha
stemspecif
antibodi
less
frequent
report
human
although
recent
shown
reactiv
human
monoclon
antibodi
vaccin
individu
abl
crossneutr
virus
antibodi
shown
bind
least
two
site
stem
region
broadli
reactiv
group
virus
altern
stemspecif
antibodi
broadli
neutral
group
influenza
virus
identifi
human
includ
similarli
antibodi
hail
abil
broadli
neutral
group
influenza
virus
broadli
neutral
antibodi
effect
group
well
group
ha
molecul
also
recogn
base
knowledg
stemspecif
antibodi
broadli
neutral
group
ha
molecul
exist
human
postul
design
univers
vaccin
induc
combin
broadli
neutral
stemspecif
antibodi
possibl
would
effect
protect
infect
influenza
virus
addit
classic
viru
neutral
antibodi
may
also
altern
antivir
properti
order
induc
antibodi
recogn
conserv
epitop
stem
region
variou
vaccin
strategi
employ
includ
use
socal
headless
immunogen
essenti
ha
molecul
lack
globular
head
domain
maintain
structur
integr
stem
mice
vaccin
dna
encod
headless
ha
follow
boost
vlp
contain
headless
ha
protein
challeng
headless
ha
vaccin
strategi
result
product
immun
sera
broader
reactiv
fulllength
ha
use
although
steril
protect
achiev
mice
challeng
homolog
viru
show
mortal
partial
protect
weight
loss
altern
strategi
induc
stemspecif
antibodi
involv
repeat
vaccin
chimer
ha
molecul
contain
stem
region
differ
globular
head
domain
use
strategi
antibodi
respons
stem
region
boost
vaccin
respons
globular
head
primari
respons
approach
show
consider
promis
univers
vaccin
candid
na
surfac
glycoprotein
import
influenza
viru
releas
cell
date
subtyp
na
identifi
design
sinc
specif
na
activ
consid
nalik
protein
na
appear
conserv
ha
howev
immunodomin
naspecif
antibodi
commonli
detect
follow
natur
infect
vaccin
abl
decreas
sever
diseas
reduc
viral
shed
howev
gener
capabl
induc
steril
immun
naspecif
antibodi
classic
consid
neutral
like
mechan
mediat
reduct
diseas
sever
block
viru
releas
infect
cell
antibodi
conserv
na
epitop
enzymat
activ
site
shown
inhibit
enzymat
activ
well
influenza
b
lineag
vivo
vaccin
studi
still
lack
induct
naspecif
antibodi
alon
regardless
broadli
reactiv
consid
undesir
strategi
univers
vaccin
product
would
result
infectionpermiss
vaccin
howev
remain
consider
interest
vaccin
candid
combin
antigen
exampl
shown
administ
combin
multimer
form
pandem
ha
na
vaccin
ferret
na
contribut
strongli
protect
ha
wohlbold
et
al
elabor
role
na
univers
vaccin
antigen
review
matrix
protein
rel
conserv
transmembran
ion
channel
import
uncoat
viru
particl
receiv
signific
attent
candid
antigen
univers
vaccin
develop
extracellular
domain
protein
consist
amino
acid
appear
attract
target
due
surfac
local
high
level
conserv
linear
natur
peptid
sinc
antibodi
thought
mostli
nonneutr
propos
immunolog
mechan
mediat
protect
adcc
also
role
alveolar
macrophag
demonstr
mous
model
inde
mode
action
depend
presenc
although
much
like
na
neglig
quantiti
antibodi
detect
follow
natur
infect
novel
techniqu
appear
overcom
initi
immunogen
issu
origin
hepat
b
core
proteinlink
vaccin
candid
improv
upon
express
multipl
sequenc
tandem
vaccin
combin
differ
adjuv
immunogen
intraperiton
intranas
administr
full
protect
lethal
strain
influenza
challeng
shown
mous
model
combin
product
system
circumv
eggbas
method
possibl
intranas
vaccin
high
immunogen
spur
phase
clinic
trial
vaccin
acamflua
sanofi
pasteur
sinc
shown
good
safeti
high
level
seroconvers
numer
product
system
test
discuss
novel
antigen
deliveri
head
nonneutr
antibodi
mount
highli
conserv
intern
protein
np
pa
may
contribut
clear
influenza
virusinfect
cell
although
exact
mechan
clearanc
mediat
remain
larg
unclear
shown
np
may
transient
express
cellular
surfac
thu
offer
target
antibodi
bind
possibl
subsequ
neutral
adcc
studi
requir
elucid
exact
mechan
interact
context
influenza
viru
infect
protect
infect
although
nonneutr
antibodi
conserv
protein
alon
may
suffici
broad
immun
evid
mount
import
conjunct
exampl
cell
mediat
immun
possibl
npspecif
antibodi
lead
opson
improv
antigen
uptak
antigen
present
cell
subsequ
antigen
cross
present
although
could
demonstr
vitro
although
cell
mediat
immun
cmi
influenza
viru
infect
prevent
infect
significantli
decreas
viral
shed
reduc
diseas
sever
mortal
lymphocyt
tend
preferenti
recogn
conserv
intern
protein
greater
potenti
broad
respons
inde
cmi
repeatedli
shown
contribut
respons
homolog
heterolog
viru
challeng
protect
viru
heterolog
subtyp
known
heterosubtyp
immun
demonstr
cell
play
crucial
role
develop
anim
model
mice
ferret
macaqu
human
protect
role
preexist
viru
specif
cell
also
demonstr
experiment
infect
natur
infect
pandem
viru
studi
employ
adopt
transfer
cell
prime
donor
naiv
recipi
mice
contribut
understand
function
cell
protect
wealth
evid
exist
import
cell
viral
clearanc
convers
cell
thought
import
predominantli
gener
mainten
memori
cell
antibodi
product
review
vaccin
focus
induct
cell
respons
potenti
univers
vaccin
howev
number
obstacl
overcom
effect
induc
adequ
respons
viral
protein
must
endogen
produc
order
effici
process
present
major
histocompat
complex
mhc
cell
number
novel
vaccin
platform
develop
allow
discuss
anoth
factor
taken
consider
design
peptid
antigen
vaccin
divers
human
leukocyt
antigen
hla
type
select
epitop
must
recogn
hla
type
develop
truli
univers
vaccin
two
import
intern
protein
regard
candid
univers
vaccin
develop
nucleoprotein
np
matrix
protein
polymeras
subunit
pa
receiv
less
attent
may
also
interest
target
nucleoprotein
np
structur
protein
encapsid
influenza
viru
rna
genom
key
function
rna
transcript
replic
packag
highli
conserv
among
differ
influenza
subtyp
np
peptid
present
mhc
class
molecul
among
import
target
host
cell
way
knowledg
employ
univers
vaccin
develop
discuss
altern
vaccin
platform
head
matrix
protein
influenza
protein
play
import
structur
function
role
viral
life
cycl
structur
form
layer
viral
envelop
ribonucleoprotein
rnp
combin
genom
rna
viral
polymeras
np
protein
function
drive
viral
bud
help
control
intracellular
traffick
highli
conserv
epitop
consensu
sequenc
employ
variou
vaccin
platform
exampl
one
epitop
interest
immunodomin
hlaa
restrict
epitop
recent
shown
present
hlaa
also
hlac
molecul
interest
highli
conserv
epitop
function
constraint
sinc
mutat
toler
without
loss
viral
fit
progress
improv
knowledg
protect
antigen
target
describ
advent
new
techniqu
everincreas
number
platform
gener
univers
vaccin
becom
avail
techniqu
employ
numer
way
deliv
desir
antigen
addit
system
often
allow
differ
rout
administr
turn
steer
type
immun
respons
induc
novel
platform
offer
promis
two
improv
influenza
vaccin
induct
broadli
protect
immun
reduc
product
time
viral
vector
recombin
noninfluenza
virus
engin
express
influenza
viral
protein
sever
advantag
use
attenu
replic
defici
viral
vector
vaccin
platform
univers
vaccin
previous
mention
cellular
immun
respons
appear
play
pivot
role
protect
influenza
infect
especi
broad
heterosubtyp
immun
desir
subunit
protein
whole
split
inactiv
virus
often
induc
antibodi
tcell
respons
due
exclus
antigen
present
mhc
class
ii
advantag
use
viral
vector
drive
de
novo
synthesi
protein
infect
cell
facilit
endogen
antigen
process
present
mhc
class
ii
molecul
thu
induc
complet
spectrum
cellular
humor
immun
respons
addit
may
stimul
mucos
immun
depend
rout
administr
thu
function
much
like
exist
laiv
vaccin
without
mani
safeti
product
issu
viral
vector
may
actual
abl
act
adjuv
immun
system
mount
respons
protein
interest
vector
consequ
vaccin
even
potenti
use
bival
vaccin
induc
immun
vector
origin
transgen
influenza
viru
protein
convers
may
requir
host
immunolog
naiv
vector
preexist
immun
vector
could
potenti
interfer
induct
immun
foreign
protein
interest
concern
vector
exampl
use
newcastl
diseas
viru
includ
possibl
recombin
revers
virul
chicken
dna
virus
adenoviru
herpesviru
baculoviru
poxviru
use
gener
recombin
influenza
viru
vaccin
date
vector
express
influenza
viru
ha
gene
commonli
use
recent
antigen
np
also
employ
either
alon
combin
ha
notabl
price
et
al
shown
immun
mixtur
adenovirus
express
np
confer
heterosubtyp
immun
even
reduc
transmiss
mous
model
simultan
express
surfac
intern
protein
potenti
induc
humor
cell
mediat
immun
therefor
make
platform
interest
candid
develop
univers
vaccin
one
particularli
promis
candid
univers
influenza
vaccin
product
modifi
vaccinia
ankara
mva
vector
mva
avian
adapt
produc
infecti
progeni
upon
infect
mammalian
cell
howev
express
earli
intermedi
abund
late
gene
product
cell
therefor
make
safe
effect
import
potenti
preexist
immun
mva
vector
induc
vaccinia
viru
vaccin
small
pox
repeat
vaccin
vector
interfer
immunogen
mani
differ
influenza
viru
protein
express
mva
vector
includ
ha
pandem
ha
combin
np
np
combin
interestingli
shown
prime
adenovir
vector
np
follow
boost
provid
better
heterolog
protect
use
either
recombin
vector
alon
recombin
mva
evalu
clinic
trial
shown
effect
safe
practic
altern
current
vaccin
strategi
therefor
mva
consid
promis
altern
vaccin
platform
univers
influenza
vaccin
develop
besid
dna
viral
vector
rna
viral
vector
also
consid
express
influenza
viru
protein
includ
paramyxoviru
flaviviru
retroviru
coronaviru
alphaviru
bunyaviru
rhabdoviru
rna
viru
vector
receiv
less
attent
dna
vector
novel
antigen
deliveri
system
univers
influenza
vaccin
interest
properti
replic
rna
virus
take
place
predominantli
cytoplasm
infect
cell
therefor
requir
transloc
nucleu
theori
would
allow
quicker
dissolut
vector
furthermor
rna
virus
except
retrovirus
pose
risk
integr
host
genom
howev
vector
also
less
stabl
smaller
genom
consequ
also
smaller
capac
introduct
transgen
vaccin
dna
plasmid
encod
influenza
viral
antigen
investig
potenti
univers
influenza
viru
vaccin
strategi
practic
advantag
includ
rapid
product
flexibl
antigen
exchang
safeti
use
highli
pathogen
virus
antigen
express
situ
humor
cellular
respons
induc
repeatedli
shown
anim
model
clinic
trial
far
moder
success
sinc
plasmid
dna
poorli
immunogen
human
potenti
could
improv
altern
deliveri
system
use
adjuv
regard
safeti
dna
vaccin
concern
rais
integr
construct
vaccin
recipi
genom
well
possibl
induc
toler
newer
techniqu
selfamplifi
mrnabas
vaccin
also
appear
show
promis
preclin
studi
viruslik
particl
vlp
compos
vitro
gener
selfassembl
viral
compon
serv
vehicl
influenza
viral
antigen
choic
commonli
ha
na
theoret
feasibl
antigen
share
featur
actual
viru
particl
import
differ
although
abl
enter
cell
abl
replic
lack
viral
genom
lack
replic
recipi
consequ
type
magnitud
immun
respons
induc
advantag
mostli
practic
effici
easi
produc
safe
platform
potenti
allow
rapid
product
vaccin
pandem
situat
confirm
pandem
phase
ii
clinic
trial
conduct
healthi
adult
show
vaccin
safe
immunogen
virosom
consid
subset
vlp
essenti
influenza
viru
envelop
lack
genet
materi
origin
viru
consist
phospholipid
bilay
incorpor
surfac
glycoprotein
ha
na
vaccin
platform
shown
safe
potenti
effect
exist
vaccin
induc
protect
antibodi
titer
licens
sever
european
countri
virosom
predominantli
induc
strong
antibodi
respons
also
shown
offer
superior
convent
subunit
vaccin
induct
cellular
immun
respons
postul
may
achiev
cellular
respons
hamedi
virosom
entri
cell
mimick
infect
deliveri
antigen
cytoplasm
present
mhc
class
molecul
addit
immunogen
virosom
enhanc
use
lipophil
adjuv
howev
scope
univers
vaccin
still
limit
produc
detergenttr
whole
influenza
viru
thu
face
similar
vaccin
product
constraint
exist
vaccin
common
limit
aforement
novel
platform
also
exist
influenza
vaccin
remain
limit
immunogen
adjuv
aluminum
salt
use
boost
immunogen
human
vaccin
decad
alum
howev
limit
effect
improv
immunogen
influenza
viru
vaccin
oilinwat
combin
shown
much
effect
licens
use
season
pre
pandem
vaccin
prepar
respect
besid
sole
increas
immunogen
adjuv
play
import
role
facilit
increas
speed
vaccin
avail
less
viral
antigen
requir
per
dose
dosespar
mean
dose
becom
avail
short
period
time
addit
adjuv
may
help
achiev
aim
univers
influenza
vaccin
increas
breadth
immun
respons
note
oilinwat
adjuv
rais
quantiti
crossreact
antibodi
howev
may
mere
reflect
overal
increas
humor
respons
also
increas
previous
unnot
broadli
reactiv
antibodi
level
detect
threshold
convent
inactiv
influenza
vaccin
induc
viru
specif
cell
respons
ineffici
indic
cell
highli
crossreact
contribut
heterosubtyp
immun
use
specif
adjuv
may
help
improv
cellmedi
immun
respons
exampl
saponin
base
adjuv
like
iscom
transloc
antigen
across
membran
antigen
present
cell
thu
promot
endogen
rout
antigen
process
present
inde
use
type
adjuv
result
increas
viru
specif
cell
respons
demonstr
anim
model
clinic
trial
review
develop
quest
univers
influenza
vaccin
novel
approach
advanc
clinic
trial
other
test
anim
model
show
promis
howev
note
vaccin
strategi
depend
least
influenc
preexist
influenzaspecif
immun
normal
situat
human
vaccin
andor
infect
multipl
time
throughout
life
result
complex
infect
histori
shape
intric
immunolog
landscap
virtual
imposs
adequ
mimic
situat
anim
model
model
may
therefor
repres
situat
immunolog
naiv
popul
cours
would
relev
use
univers
influenza
vaccin
pediatr
popul
influenza
virus
continu
import
threat
public
health
although
much
progress
made
way
univers
vaccin
mani
new
approach
show
theoret
promis
still
verifi
anim
model
human
promis
univers
influenza
vaccin
candid
like
induc
broad
humor
cell
mediat
respons
true
univers
vaccin
becom
realiti
attent
must
paid
pandem
prepared
thu
increas
speed
vaccin
product
platform
mva
show
much
promis
decreas
respons
time
outbreak
situat
truli
univers
influenza
vaccin
nt
quit
nail
yet
lidewij
c
wiersma
guu
f
rimmelzwaan
rori
de
vri
wrote
manuscript
author
declar
conflict
interest
